Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146352 · ClinicalTrials.gov registry record · NA
AXIOS Stent With Electrocautery Enhanced Delivery System
A NA study of Pancreatic Pseudocyst(s), sponsored by Xlumena.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT02146352: Completed NA study of Pancreatic Pseudocyst(s), sponsored by Xlumena.
NCT02146352 is a NA study of Pancreatic Pseudocyst(s) that has completed, run by Xlumena. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02146352, a NA study of Pancreatic Pseudocyst(s), has completed, sponsored by Xlumena.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
Primary Outcome
Freedom from access site-related bleeding requiring transfusion
Conditions Studied
Interventions
- DEVICE AXIOS Stent with Electrocautery Enhanced Delivery System
Study Locations (8)
Florida
- Baptist Medical Center - Jacksonville
- Florida Hospital - Orlando
Colorado
- University of Colorado Denver - Aurora
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
| Phase | NA |
What the finished NCT02146352 record still lists
NCT02146352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pancreatic Pseudocyst(s) appearing as the primary indexed condition, and to 1 intervention - of which AXIOS Stent with Electrocautery Enhanced Delivery System is the first listed.
NCT02146352 lists 8 locations in 7 states (Florida, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT02146352 about?
NCT02146352 is a clinical study titled "AXIOS Stent With Electrocautery Enhanced Delivery System". The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
What is the current status of trial NCT02146352?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2015-03.
What conditions does trial NCT02146352 study?
This clinical trial studies the following conditions: Pancreatic Pseudocyst(s).
What interventions are being tested in trial NCT02146352?
The interventions under investigation include: AXIOS Stent with Electrocautery Enhanced Delivery System (DEVICE).
Who is sponsoring clinical trial NCT02146352?
This trial is sponsored by Xlumena, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02146352 being conducted?
This trial has 8 study locations across Colorado, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02146352's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia